Other languages Rallybio Corporation

Equities

RLYB

US75120L1008

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-17 EDT			5-day change	1st Jan Change
1.45 ^USD	-6.15%		-4.92%	-39.33%

05-15	JPMorgan Downgrades Rallybio to Neutral From Overweight	MT
05-09	Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09
Ralebio Corporation Announces the Presentation of Results from FNAIT Systematic Literature Review and Meta- Analysis At the Academy of Managed Care Pharmacy 2024 Annual Meeting	04-17
Top Premarket Decliners	04-12
US Equity Markets Close Mixed After March Producer Price Inflation Data	04-11
Sector Update: Health Care Stocks Softer Late Afternoon	04-11
Aktien New York: Dow erholt sich vor Start in die Berichtssaison	04-11
Top Midday Gainers	04-11
Aktien New York: Dow schwächer vor Start in die Berichtssaison	04-11
Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet	04-11
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Another Key Inflation Report	04-11
Top Premarket Gainers	04-11
Rallybio Corporation Announces Collaboration with Johnson & Johnson	04-10
Rallybio Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-12
Rallybio Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-12
Rallybio Corporation Announces the Prioritization of Its Portfolio and a 45% Workforce Reduction to Focus Resources on Its Phase 2-Ready Clinical Stage Programs	02-06
Rallybio Corporation Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116	12-20
Rallybio Corporation Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212	11-28
Rallybio Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Rallybio Corporation Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting	11-02
Rallybio Corporation Presents Phase 1 Single Ascending Dose Data for RLYB116, Innovative Subcutaneously Injected Inhibitor of Complement Component 5	23-09-03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Rallybio Corporation

Equities

RLYB

US75120L1008

Other languages

Filters